Tyme Technologies Inc

Tyme Technologies — Investor Presentation (December 2016)

30 slides from Tyme Technologies's investor presentation, Dec 30, 2016

  1. Slide 1: Tyme Technologies Investor Presentation, December 2016

    Logicum | Scientia | Humanitas December 2016 1

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Certain statements in this presentation and associated oral statements are "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements are based on our current expectations and beliefs and are subject to a n

  3. Slide 3: Tyme Development Overview

    Tyme Development Overview • Tyme is developing cancer therapeutics that take advantage of cancer’s differentiated metabolism • SM-88, Tyme’s lead candidate has shown compelling evidence as monotherapy across multiple cancer types SM-88 Phase I Summary 30 end-stage metastatic patients that had failed

  4. Slide 4: SM-88 Development Plan

    SM-88 Development Plan Ongoing and Planned Programs Participating • Expanded Access Program shows supportive results to Institutions Phase I trial  57 patients have evaluable data  CR: 7/57, PR: 19/57, SD: 19/57 (79% total benefit)  No drug related SAEs  Conducted at over 10 institutions • Overa

  5. Slide 5: SM-88 has Demonstrated Effectiveness against the Most Common and Deadly Cancers

    SM-88 has Demonstrated Effectiveness against the Most Common and Deadly Cancers All patients had end-stage progressive metastatic disease at the time of SM-88 therapy initiation Primary Disease 2016 US Data (1) SM-88 ORR (2) Estimated Estimated 5-Year Complete Partial New Cases Deaths Survival Respo

  6. Slide 6: Scientific Overview

    SCIENTIFIC OVERVIEW 6

  7. Slide 7: Understanding Cancer Metabolism

    Understanding Cancer Metabolism • Cancer is largely reliant on anaerobic metabolism, which can be Cancer has a ~10x less productive than normal aerobic metabolism predisposition for • Rapid cancer cell proliferation requires substantially more energy inefficient anaerobic generation than normal cell

  8. Slide 8: SM-88's Metabolic Strategy

    SM-88’s Metabolic Strategy Increase need for amino acids in metabolism (ketotic state) 1  Cancer cells are exponentially affected due to glycolytic metabolism Insert a corrupted amino acid used by the tumor for mucin production 2  Proprietary approach employs a drug that is utilized like tyrosine,

  9. Slide 9: Clinical Results

    CLINICAL RESULTS 9

  10. Slide 10: Phase I: Clinical Study of SM-88

    Phase I: Clinical Study of SM-88 Population Summary Patient Overview • Enrolled 30 patients between Progressive disease 26/30 January and December 2012 Recurrent disease 4/30 • All patients had end-stage Prior surgery 53% metastatic cancer Prior radiation 33% - Expected survival 3-6 months - All had

  11. Slide 11: Phase I: Best Overall Response

    Phase I: Best Overall Response All Subjects (n = 30), Monotherapy with SM-88 Number of Primary Disease Best Overall Response Clinical Benefit PD Patients CR PR SD CR+PR+SD Breast Cancer 14 2 4 5 78.6% (11) 3 Lung Cancer 5 0 1 4 100.0% (5) 0 Pancreatic Cancer 3 0 0 3 100.0% (3) 0 Prostate Cancer 2 0

  12. Slide 12: Phase I: Progression Free Survival

    Phase I: Progression Free Survival All Subjects (n = 30), Monotherapy with SM-88 50% SM-88 PFS: 14.7 months P<0.05 12

  13. Slide 13: Phase I: Progression Free Survival

    Phase I: Progression Free Survival Subgroup Analysis Where Penultimate PFS Available (n = 19) Median Penultimate Median SM-88 PFS: 4 months PFS: 11 months • 2.8x longer PFS on SM-88 than last therapy prior to SM-88 • Statistically significant p- value of <0.05 Study Ended Without 11 / 19 Disease Pro

  14. Slide 14: Phase I: Overall Survival

    Phase I: Overall Survival All Subjects (n = 30), Monotherapy with SM-88 32% survival at 36 months 50% SM-88 OS: 25.7 months 14

  15. Slide 15: Phase I: Safety Profile

    Phase I: Safety Profile – 30 Patients No drug-related SAEs reported and no patients discontinued treatment due to an AE Median SM-88 exposure: 16.3 weeks, (range: 6-61 weeks) Drug-related Adverse Events Reported in SM-88, Cycle 1 Number of Treated Adverse Events Subjects (n = 30) Hyperpigmentation 8

  16. Slide 16: Current Clinical Programs

    CURRENT CLINICAL PROGRAMS 16

  17. Slide 17: Summary of Clinical Programs

    Summary of Clinical Programs • A Phase Ib/II trial for monotherapy in prostate cancer was initiated and is currently enrolling patients • Open label trial with regular patient analysis • Tyme plans to begin enrolling a Phase II pancreatic cancer trial shortly • Multiple Investigator Initiated Trials

  18. Slide 18: Clinical Timeline

    Clinical Timeline Q4’16 Q1’17 Q2’17 Q3’17 Q4’17 Q1’18 Data from Expected six-month PFS Prostate Enrollment of Phase Ib/II trial initial patients and overall survival data Expected six-month PFS and Pancreatic Enrollment of Phase II trial overall survival data Lung / Glioma / Initiation of Phase II t

  19. Slide 19: Management and Advisor Biographies

    MANAGEMENT AND ADVISOR BIOGRAPHIES 19

  20. Slide 20: Senior Management

    Senior Management Steve Hoffman – Chief Executive Officer, Chief Science Officer, President and COB Steve has over 25 years of experience holding a variety of senior management positions with companies in the medical, chemistry, aerospace and laser optics fields. His research has led to collaboratio

  21. Slide 21: Scientific and Medical Advisory Board

    Scientific and Medical Advisory Board Suresh Chari, MD (Mayo Clinic) – Dr. Chari is a Professor of Medicine with the Mayo Clinic College of Medicine. He is also a consultant in the Division of Gastroenterology. He is Head of the Pancreas Interest Group in the Division of Gastroenterology and Hepatol

  22. Slide 22: Outside Directors

    Outside Directors Gerald Sokol MD, MSc, FCP – Director Dr. Sokol has been Chief of Radiation Oncology at the University of South Florida’s Tampa General Hospital and has served on the review staff of the FDA for over 27 years as a senior regulatory scientist and officer. Tommy G. Thompson – Director

  23. Slide 23: Overview

    Overview • Tyme is developing novel cancer therapeutics that take advantage of cancer’s differentiated metabolism • Our lead candidate, SM-88, is designed to break down cancer’s cellular defense while simultaneously increasing oxidative stress, a process that can lead to cell death • SM-88 has been

  24. Slide 24: Appendix

    APPENDIX 24

  25. Slide 25: Toxicology Studies

    Toxicology Studies • 7 day escalating dose and 28 day repeat dosing in rats and dogs using the tyrosine agent of SM-88. Administration daily or 3 times per week over a 4-week period at dose levels of 25, 75 and 150mg/kg • All animals demonstrated consistent pancreas volume decrease, decreased overal

  26. Slide 26: Expanded Access Program

    Expanded Access Program • 57 individual case studies were also performed with the approval of the Institutional Review Board at New York Presbyterian Lower Manhattan Number of Primary Disease Best Overall Response Clinical Benefit PD Patients CR PR SD CR+PR+SD Breast Cancer 11 0 4 3 63.6% (7) 4 Panc

  27. Slide 27: Best Overall Response: All Subjects

    Best Overall Response: All Subjects (30 Phase I and 57 Expanded Access Patients) Number of Primary Disease Best Overall Response Clinical Benefit PD Patients CR PR SD CR+PR+SD Breast Cancer 25 2 8 8 72.3% (18) 7 Pancreatic Cancer 13 1 2 8 84.6% (11) 2 Lung Cancer 8 0 1 6 87.5% (7) 1 Prostate Cancer

  28. Slide 28: Phase I: Pain and PS Scores

    Phase I: Pain and PS Scores (30 Patients) • A measureable improvement in self-reported pain with 8 subjects reporting no pain one treatment cycle (6 weeks) • 13 patients became asymptomatic after one treatment cycle Pain Scores* ECOG PS Status* Following 1 Cycle of SM-88 (n = 30) Following 1 Cycle o

  29. Slide 29: Collaborations & Investigator Initiated Trials

    Collaborations & Investigator Initiated Trials Pancreatic Mayo Clinic Collaborations (Fernandez-Zapico, PhD)  “Optimal Doublet Dose and Sequence of SM-88 with Gemcitabine and/or nab-Paclitaxel”  Preclinical animal model using PDX and GeMM Medical College of Wisconsin (D Evans, MD, Chair Surgery) 

  30. Slide 30: Tyme, Inc. Contact Information

    Steve Hoffman [email protected] Michael Demurjian [email protected] Robert Dickey IV [email protected] Giuseppe Del Priore, MD, MPH [email protected] OTC Market (OTCQB): TYMI Tyme, Inc. 44 Wall Street – 12th Floor New York, New York 10005 www.tymeinc.com 30 1

Tyme Technologies — Investor Presentation (December 2016) on 6ix